Morgan Bayer is an assistant editor for Targeted Oncology and Targeted Therapies in Oncology.
The Targeted Pulse: An Approval for Colorectal Cancer, AI Model Enhances Palliative Care, and More
June 30th 2024The FDA approved adagrasib with cetuximab for KRAS G12C-mutated CRC and an AI-driven mortality models improve palliative care. We also cover data on datopotamab deruxtecan showing promise in HER2-low breast cancer, zanubrutinib plus venetoclax achieving 100% ORR in high-risk CLL/SLL, and an overview of treatments HER2-targeted treatments highlighting T-DXd in CNS involvement.
Lifileucel Recommendations in Solid Tumors Deliver Comprehensive Guidance
June 21st 2024Recommendations on adoptive cell therapy with tumor-infiltrating lymphocytes that address the newly approved therapy lifileucel explore safe administration practices and optimal patient selection based on individual characteristics.
AI Mortality Predictor Enhances End-of-Life Care and Palliative Support
June 20th 2024In a prognostic study, an artificial intelligence model significantly outperformed oncologists in predicting short-term mortality, resulting in a 60% positive predictive value vs 34.8%, which involved 57 physicians and 17 advanced practice clinicians.
The Targeted Pulse: An In-Depth Overview on the Power of ADCs, Highlights from ASCO, and More
June 16th 2024Delving into the power of ADCs and intriguing data presented at the 2024 ASCO Annual Meeting, including benefits observed with nivolumab-cabozantinib in advanced RCC and the durable responses seen in endometrial cancer with envafolimab-lenvatinib. We also cover data on JNJ-6420 for metastatic CRPC, and the improvements seen with enfortumab vedotin plus pembrolizumab in urothelial cancer.
The Targeted Pulse: Palazestrant/Ribociclib Shows Favorable Efficacy, Approvals in SCLC, and More
May 26th 2024Interim results show promising efficacy of palazestrant/ribociclib in ER+/HER2– metastatic breast cancer, an approval for tarlatamab-dlle, and data suggesting early ctDNA kinetics as a potential pharmacodynamic biomarker. We also cover the initiation of dosing quaratusugene ozeplasmid/atezolizumab in SCLC and more.
The Targeted Pulse: Agent Exhibiting PFS Increases, Guideline Changes, Approvals, and More
May 5th 2024T-DXd enhances survival in HR+/HER2-low breast cancer, and immunotherapy combo is recommended for advanced SCLC. We also highlight recent FDA approvals and challenges associated with legislative changes.
The Targeted Pulse: A Spread of Newly Approved Agents, CAR T-Cell Box Warnings, and More
April 28th 2024Recent FDA approvals such as tovorafenib, nogapendekin, and alectinib, are included in this recap. We also cover boxed warnings for CAR T-cell therapies and analysis advancements for papillary thyroid microcarcinoma.